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Trastuzumab is established as standard care for patients with HER2-positive breast can-
cer both in the adjuvant and metastatic setting. However, 50% of the patients do not
respond to the trastuzumab therapy, and therefore new predictive biomarkers are highly
warranted. MicroRNAs (miRs) constitute a new group of biomarkers and their cellular
expression can be determined in tumor samples by in situ hybridization (ISH) analysis.
miR-21 is highly prevalent and up-regulated in breast cancer and has been linked to drug
resistance in clinical and in vitro settings. To determine expression patterns of miR-21 in
high-grade breast cancers, we examined miR-21 expression in 22 HER2-positive tumors
and 15 HER2-negative high-grade tumors by ISH.The histological examination indicated that
patient samples could be divided into three major expression patterns: miR-21 predomi-
nantly in tumor stroma, predominantly in cancer cells, or in both stromal and cancer cells.
There was no obvious difference between the HER2-positive and HER2-negative tumors
in terms of the miR-21 expression patterns and intensities. To explore the possibility that
miR-21 expression levels and/or cellular localization could predict resistance to adjuvant
trastuzumab in HER2-positive breast cancer patients, we analyzed additional 16 HER2-
positive tumors from patients who were treated with trastuzumab in the adjuvant setting.
Eight of the 16 patients showed clinical recurrence and were considered resistant. Exami-
nation of the miR-21 expression patterns and intensities revealed no association between
the miR-21 scores in the cancer cell population (p=0.69) or the stromal cells population
(p= 0.13) and recurrent disease after adjuvant trastuzumab. Thus, our findings show that
elevated miR-21 expression does not predict resistance to adjuvant trastuzumab.
Keywords: biomarker, breast cancer, HER2, miR-21, prediction, response, trastuzumab
INTRODUCTION
The human epidermal growth factor receptor-2 (HER2, NEU,
and c-ERBB-2) is a cell surface receptor tyrosine kinase that
is strongly up-regulated in more than 15% of all breast can-
cers (1), and breast cancer patients with HER2 overexpressing
tumors have poor prognosis (2, 3). HER2-directed therapy using
the humanized monoclonal antibody, trastuzumab in combina-
tion with conventional chemotherapy, improves overall survival
in patients with HER2-positive breast cancers (4). However, only
half of the HER2-positive breast cancer patients respond to the
HER2-directed therapy (5). The lack of therapeutic efficacy and
high cost of the therapeutic agent urges identification and devel-
opment of predictive markers as companion diagnostics. So far, no
clinically validated predictive markers for response to trastuzumab
have been reported.
MicroRNAs (miRs) are short non-coding RNAs that regulate
protein synthesis at the post-transcriptional level by binding to
the 3’UTR of mRNAs causing mRNA destabilization or degrada-
tion. miRs can be measured in tissues and body fluids by in situ
hybridization (ISH), qPCR, and microarray or high-throughput
sequencing, and as such, miRs constitute a relatively novel group
of biomarkers. One of the most abundant miRs in solid tumors
is miR-21. miR-21 expression is highly increased in malignant
tumors, including breast, colon, lung, and brain cancer (6, 7),
and high expression levels are associated with poor prognosis
(8–11). Solid tumors, including breast cancers, are complex tis-
sues consisting of the malignant epithelial cells and a surrounding
stroma consisting of fibroblasts, inflammatory cells, and vascular
cells. ISH studies of tissue from breast, colon, brain, pancreas, and
esophagus cancer (10–14) have shown that miR-21 is predomi-
nantly expressed in the stromal cells; however, subpopulations of
miR-21 positive cancer cells are also reported (10, 11, 15).
Some miRs are found to be indicators of drug resistance and
some even to confer drug resistance to a variety of cancer drugs
(16–18). miR-21 is one the most studied and has been found to
confer drug resistance to trastuzumab (19), 5-fluorouracil (20,
21), doxorubicin (22, 23), cisplatin (24, 25), and paclitaxel (26).
Gong et al. (19) reported that high miR-21 levels in breast cancer
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biopsies before and after neoadjuvant trastuzumab were associated
with trastuzumab resistance, and that blocking the action of miR-
21 re-sensitized resistant breast cancer cell lines to trastuzumab
(19). The authors suggested that miR-21 may function through
the tumor suppressor phosphatase and tensin homolog (PTEN),
a well-described miR-21 target protein (27–29), which has been
reported to be a potential predictor for trastuzumab resistance
(30). Thus, miR-21 may play an important role in multi-drug
resistance mechanisms.
Recent studies have indicated that drug resistance in cancer
therapy is not only related to the malignant cancer cells, but also
to cells in the stromal compartment (31–34). For example, in the
study by Alkhateeb et al. (34), high levels of inflammation mark-
ers measured in serum from HER2-positive breast cancer patients
were associated with poor response to trastuzumab-containing
therapy. Thus, molecular biomarkers derived from the breast can-
cer stroma should also be considered in the search for novel
predictive biomarkers.
In this paper, we addressed whether miR-21 ISH analysis in pri-
mary breast cancers can help to predict trastuzumab resistance in
HER2-positive breast cancer patients treated with trastuzumab in
the adjuvant setting, and whether the miR-21 expression pattern
correlated with HER2 status or other known clinical markers.
MATERIALS AND METHODS
PATIENTS
Tissue samples were separated into two sample groups, here named
reference group and study group (see also Table 1). The ref-
erence group included 36 breast cancer samples from patients
diagnosed 1999–2009 with high-grade invasive ductal carcinoma
(IDC). Among them, 21 cases were HER2-positive and 15 cases
were HER2-negative. The study group included samples from
16 HER2-positive ethnic Danish breast cancers patients. These
patients were diagnosed from 2005 to 2008 and had their primary
tumor surgically removed and received adjuvant trastuzumab
(trastuzumab/Herceptin was obtained from Roche). After surgery,
the patients received adjuvant chemotherapy, irradiation,and anti-
hormonal treatment according to national standards, and eventu-
ally trastuzumab. All patients received trastuzumab every third
week for one year. None of the patients had been treated for breast
cancer previously. Eight patients developed recurrent disease with
distant metastases after 5–8 years of follow up. In the present study,
we considered these patients as resistant to trastuzumab. Patients
without recurrence were considered sensitive. All samples were
obtained from the local tissue bank (Herlev Hospital, Copenhagen,
Denmark) as formalin-fixed paraffin-embedded (FFPE, here fixed
Table 1 | Patients included in this study.
n Age (range) Diagnosis HER2 HER2
year neg (n) pos (n)
Reference group 36 62 (36–92) 1999–2009 15 21
Study group 16 51 (33–68) 2005–2008 0 16
Age range and year range of diagnosis are indicated for the reference group and
study group.
within 1 h of surgery by 24–72 h incubation in formalin at room
temperature). Tumor grade was based on HE stained sections. The
study was performed in accordance with permission given by The
Regional Scientific-Ethical Committee for Copenhagen, Denmark
(J. nr. H-3-2014-010).
IMMUNOHISTOCHEMISTRY
Immunoperoxidase staining for clinical biomarkers included
staining for ER (mAb clone SP1, Dako, Glostrup, Denmark), PR
(mAb clone PqR636, Dako), P53 (mAb clone DO7, Dako), Ki67
(mAb clone Mib1, Dako), and HER2 (mAb clone 4B5, Roche).
For ER (RTU), PR (mAb diluted 1:100), P53 (mAb diluted 1:200),
and Ki67 (mAb diluted 1:200), 3–5µm tissue sections were pre-
treated using DakoLink and stained in a Dako immunostainer,
whereas HER2 staining was performed using a Ventana instru-
ment (Ventana) according to the manufacturers guidelines. Scores
of ER, PR, p53, and Ki67 were the percentage of positive cancer
cells. The IHC scores of HER2 were performed in accordance with
the HercepTest™ Interpretation Manual – Breast (Dako, Glostrup,
Denmark).
HER2 FISH
Cases that scored 2 in HER2 immunoperoxidase staining were
additionally tested by FISH analysis using the HER2 FISH phar-
mDx™ Kit-K331 (Dako, Glostrup, Denmark) according to the
manufacturers’ instructions.
MicroRNA-21 IN SITU HYBRIDIZATION AND SCORING
Automated miR-21 ISH was performed on a Tecan Genepaint
instrument (Tecan, Switzerland) essentially as described previ-
ously (10). In brief, deparaffinized sections were treated with
proteinase-K (25µg/mL for 8 min at 37°C). Double-FAM-labeled
miR-21 and scrambled LNA™ probes (Exiqon, Vedbæk, Den-
mark) were incubated at 30 nM for 1 h in Exiqon hybridization
buffer (Exiqon) at 57°C. The probes were detected with alkaline-
phosphatase conjugated anti-FAM (1:800, Roche) for 30 min at
30°C and then incubated with freshly prepared NBT-BCIP sub-
strate containing 0.2 nM levamisole for 1 h at 30°C. For scoring of
the miR-21 ISH staining, we obtained digital whole slides using
a Hamamatsu scanner (20× objective). The miR-21 staining was
scored at the level of cellular tissue compartments, stromal vs.
cancer cells, and at the level of staining intensity/density (0, 1, 2,
or 3). Score 0, indicated no staining or similar staining as back-
ground level, score 1 indicated staining in a subset of cells that
could be weak or intense (up to 10%), score 2 indicated staining in
a larger subset of cells (10–50% of the cells) that could be weak or
intense, and score 3 indicated intense staining in virtually all cells
of the tissue compartment (examples of miR-21 scores are shown
in Figure 1). Scoring was performed independently blinded by
two observers (Eva Balslev and Boye Schnack Nielsen ). If the dif-
ference between scores was more than one, a consensus score was
determined. The averages of the two scores are presented.
MicroRNA-21/HER2 DOUBLE STAINING
MicroRNA-21 ISH combined with immunohistochemical stain-
ing for HER2 was performed essentially as described (35). After
proteinase-K treatment, sections were hybridized with 20 nM
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FIGURE 1 | MicroRNA-21 expression patterns and scoring in grade 3
breast cancers. Representative miR-21 ISH expression patterns and
intensities in HER2-positive (A–F) and HER2-negative tumors (G–I). The
miR-21 ISH signal (dark blue staining, examples indicated by arrows in (A)) is
seen exclusively in stromal cells (A,D,F, and G), or in both stromal cells and
cancer cells (B,C,E,H, and I). Stromal and cancer cell tissue compartments
are indicated by St and Ca, respectively. In (D,G, and H), arrows indicate
miR-21 positive stromal cells. The variations in miR-21 ISH signal intensity
and prevalence of positive cells were scored 0, 1, 2, or 3 by two observers
(see Material and Methods section) in both cancer and stromal cells. The
miR-21CC and miR-21St scores are indicated (miR-21CC/miR-21St). All sections
were counter stained with nuclear fast red. The examples are from tumors in
the reference group and are representative for the individual tumors. Bar:
50µm.
miR-21 LNA probe for 1 h, and the probe was detected with
peroxidase-conjugated anti-FAM (Roche) followed by incuba-
tion tyramine-signal-amplification (TSA)-Cy5 substrate for 5 min
at room temperature. Polyclonal rabbit anti-ErbB-2 (ab2428,
AbCam, Cambridge, UK) was incubated at room temperature
and detected with Cy3-conjugated goat anti rabbit (Jackson
ImmunoResearch, West Grove, PA, USA). Slides were mounted
with Antifade Gold with DAPI (Invitrogen).
STATISTICS
Spearman’s rank correlation analyses of miR-21 scores and known
clinical parameters were conducted to obtain Spearman rank cor-
relation coefficients, r. The differences in miR-21 scores between
HER2-positive and HER2-negative, and trastuzumab-sensitive
and -resistant patient groups were evaluated using the non-
parametric Mann–Whitney U test. Statistical significance was
considered at the 5% probability level (p< 0.05). All statistical
analyses and calculations were performed with GraphPad Prism 5
(GraphPad Sofware, La Jolla, CA, USA).
RESULTS
PATIENTS
The patient material is briefly described in Table 1. The patient
samples in the reference group were used to delineate miR-21
expression patterns and intensities in high-grade breast cancers
and to establish a miR-21 scoring system. The miR-21 scores were
compared with known clinical parameters, including the HER2
status. The samples in the study group were used to evaluate
the miR-21 expression patterns and intensities, to obtain miR-
21 scores for correlation with recurrence of disease after adjuvant
trastuzumab.
MicroRNA-21 EXPRESSION PATTERNS AND SCORING
MicroRNA-21 ISH was performed in parallel on the 36 samples
on an automated platform. miR-21 ISH signal was seen in all
cases with variation both in staining intensity and in localization.
Among the 36 tumors, all showed staining in tumor stromal cells,
mostly fibroblasts, but probably also inflammatory and endothe-
lial cells were positive. The stromal miR-21 staining varied from
confined focal staining, with most intense staining in the fibroblas-
tic cells surrounding islands of cancer cells, to staining involving
most of or the whole tumor stroma. Using a semiquantitative
approach, we scored the miR-21 stroma staining (miR-21st) grad-
ually 1, 2, or 3 as described in Material and Methods section
(examples in Figure 1). miR-21 ISH signal was also prevalent
in cancer cells (miR-21CC) in 23 of the cases, and the positive
reaction was scored 0, 1, 2, or 3 in terms of staining intensity
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FIGURE 2 | MicroRNA (miR)-21 scores in the HER2 reference group.The miR-21 scoring was performed as described in Material and Methods section, here
presented as average scores of two observers: miR-21CC (A) and miR-21St (B).
Table 2 | Correlation analyses.
n miR-21St ER PR Ki67 P53
miR-21CC HER2 pos 21 −0.31 −0.07 0.03 −0.24 0.03
HER2 neg 15 −0.14 0.38 0.56* −0.04 0.35
All 36 −0.22 0.07 0.22 −0.15 0.15
n miR-21CC ER PR Ki67 P53
miR-21St HER2 pos 21 −0.31 0.11 0.19 −0.19 −0.24
HER2 neg 15 −0.14 −0.26 0.13 −0.17 −0.37
All 36 −0.22 −0.07 0.14 −0.22 −0.26
Spearman correlation analyses of miR-21 scores (cancer cell expression, miR-
21CC and stromal expression, miR-21St) and available clinical parameters here
separated into HER2-negative and positive tumors (Spearman correlations,
*p<0.05).
(examples in Figure 1). In general, miR-21 ISH signal was equally
intense in all stained tumor cells in the same tumor, however,
some variations were observed. Most dramatic variation was seen
in two cases (both HER2-negative) in which one tumor cell com-
partment showed strong staining, whereas an adjacent tumor cell
compartment showed virtually no staining (data not shown). In
these two cases the scores presented are those with highest stain-
ing intensity. Intensely stained myoepithelial cells surrounding
foci of carcinoma in situ (CIS) were seen in 8 of the 36 cases
(data not shown). No ISH signal was obtained with the scramble
probe in any of the samples. Additional specificity analyses of the
miR-21 ISH probe in breast cancer samples have been performed
previously (12).
MicroRNA-21 LOCALIZATION AND HER2 STATUS AND OTHER CLINICAL
PARAMETERS
There was no obvious difference in the miR-21CC expression
pattern or miR-21St expression pattern when comparing HER2-
positive with HER2-negative cases (Figure 2), suggesting that
the miR-21 expression pattern is independent of the HER2 sta-
tus. A series of additional molecular parameters were obtained
from the cohort by immunohistochemistry: ER, PR, Ki67, and
p53 and then correlated with the miR-21 scores (Table 2). In
HER2-negative tumors, we noted a significant positive correlation
(p= 0.04) between miR-21CC and elevated PR. Otherwise, none of
these parameters showed significant correlation with the two miR-
21 scores, miR-21CC and miR-21St. We have previously reported
that increased stromal miR-21 levels in grade 1 and 2 lesions are
associated with increased cancer cell proliferation as measured by
the Ki67 index (12). We did not see a similar correlation in these
grade 3 lesions.
MicroRNA-21 CO-LOCALIZES WITH HER2
In order to perform double fluorescence analysis of HER2 and
miR-21, we employed a polyclonal antibody, which was compatible
with the proteinase-K-directed antigen retrieval needed for miR
ISH on FFPE samples. Six samples from the reference group were
selected for miR-21/HER2 double immunofluorescence based
on (1) the intense staining for HER2 with the polyclonal anti-
body and (2) the miR-21CC and/or miR-21St positive staining. As
expected, we found miR-21 ISH signal in HER2-positive cancer
cells (Figure 3). We noted that the miR-21 staining intensity in
HER2-positive cancer cells varied from absent to strongly posi-
tive. For comparison, in a case with prevalent stromal miR-21, we
found miR-21 positive stromal cells surrounding HER2-positive
clusters of cancers cells (Figure 3).
MicroRNA-21 STAINING PATTERNS AND RECURRENCE AFTER
HER2-DIRECTED THERAPY
MicroRNA-21 ISH was then performed in parallel on the 16
HER2-positive cases with known disease status after adjuvant
trastuzumab. Eight of the patients experienced no recurrent
disease after treatment within the 5–8 years follow-up period
(sensitive tumors), whereas the other eight patients experienced
recurrent disease (resistant tumors). Examination of the miR-
21 staining patterns in these samples indicated expression pat-
terns similar to those observed in the reference group, thus both
tumors with predominant miR-21CC and miR-21St were present
(Figure 4). However, there was no significant difference in the
miR-21CC and miR-21St as well as in the summarized total aver-
age miR-21 scores, when comparing resistant and sensitive tumors
(Mann–Whitney U test). Thus, we found no indications that
miR-21 expression patterns could help to identify HER2-positive
patients resistant to adjuvant trastuzumab in this study group.
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FIGURE 3 | Double staining for miR-21 and HER2 in HER2-positive breast
cancers.Tissue sections were processed first for miR-21 ISH and
subsequently for HER2 IHC. The figure shows three cases (A–D), (E–H) and
(I–L). miR-21 was detected using TSA-Cy5 substrate (white) and HER2 with
Cy3-conjugated anti-rabbit antibody (red). All sections were counterstained
with DAPI (blue). miR-21 ISH signal is seen in HER2-positive cancer cells in
cases (A–D) and (E–H) [examples are indicated by arrows in (A–D)], whereas
HER2-positive cancer cells in case (I–L) are miR-21-negative. The examples
are from tumors in the reference group and are representative for the three
tumors. Bars: 20µm.
FIGURE 4 | MicroRNA-21 scores in the HER2 study group.The miR-21
scores for cancer cell-associated miR-21 expression, miR-21CC (A), miR-21
stromal expression, miR-21St (B), and the total summarized miR-21 scores
(C). The scores are averages of two observers and here presented in scatter
grams. Mann–Whitney U test: p=0.69 for miR-21CC, p=0.13 for miR-21St,
and p=0.20 for total miR-21.
DISCUSSION
MicroRNA-21 is one of the most prevalent miRs in solid tumors,
and increased expression levels are associated with poor prognosis
both in untreated early-stage colon cancer patients (8, 10, 15) and
in breast and colon cancer patients treated with chemotherapy (8,
9, 36, 37). In addition, several recent studies have suggested that
miR-21 confers drug resistance to cancer cells in vitro (38, 39),
including resistance to trastuzumab treatment of HER2-positive
patients (19). We assumed that if miR-21 indeed confers drug
resistance in HER2 breast cancer patients, knowing the specific cel-
lular origin of miR-21 in the tumors may help to predict response
to HER2-directed therapy. In this study, we show that miR-21
is highly expressed in high-grade breast cancers, both in HER2-
positive and negative cases, and that miR-21 ISH signal can be seen
in both stromal cells and cancer cells in varying expression levels.
Gong et al. (19) found increased miR-21 ISH signal in resis-
tant tumors before and after trastuzumab-directed therapy, and
showed that miR-21 antisense oligonucleotides could restore
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trastuzumab sensitivity in resistant cells by inducing PTEN expres-
sion, suggesting that miR-21 mediates trastuzumab resistance and
that antagonizing miR-21 in a therapeutic setting could sensi-
tize cancer cells to HER2-directed therapy. Indeed, we found
that both miR-21 ISH signal and HER2 immunoreactivity are
seen in the same cancer cells, which would be a prerequisite for
successful combination of anti-miR-21 and HER2-directed ther-
apy. In order to assess if miR-21CC expression could predict the
response to trastuzumab therapy, we examined the cellular expres-
sion of miR-21CC in 16 HER2-positive tumors, half of which
relapsed within the 5–8 years follow-up period after adjuvant
trastuzumab. However, since we also found miR-21CC expression
in trastuzumab-sensitive tumors at the same frequency, our find-
ings do not indicate that high miR-21CC can predict recurrence.
Based on our studies of 16 patients treated in the adjuvant setting,
our observations imply that miR-21 did not confer trastuzumab
resistance, a finding which appears inconsistent with the con-
clusion drawn by Gong et al. (19), who investigated 32 patients
treated in the neoadjuvant setting. However, the major difference
in treatment protocols of the two studies does not justify a direct
comparison of the results.
Although the relatively small sample size offered little statistical
strength to our observations, it should be noted that the con-
comitant adjuvant chemotherapy may have been a confounding
factor that prevented identification of a direct link between miR-
21 expression and trastuzumab resistance. Likewise, small patient
groups will be relatively sensitive to genetic variation, which in our
case may also have contributed to cover the impact of miR-21 as a
predictive biomarker. Another parameter that may have prevented
identification of a direct link between miR-21 and trastuzumab
resistance is the semiquantitative scoring approach employed. In
order to minimize experimental variation in staining intensities,
all sections, both in the reference group and in the study group,
were processed identically and stained in parallel on an automated
platform. Manual scoring was then performed on digital whole
slides by two observers, and since considerable variation between
samples could easily be discriminated,we assumed that our scoring
approach was not a limiting factor. Furthermore, a manual scoring
approach could potentially be implemented in the daily diagnosis.
In previous studies, we used image analysis to obtain quantita-
tive estimates of miR-21 expression (10, 12, 15), but common for
those studies, the expression patterns were more homogenous.
Here, the cellular origin of expression was a key parameter. It can-
not be excluded that alternative semiquantitative approaches may
have classified the cases better. For example, RT-qPCR analyses
of microdissected tissue compartments, stroma and cancer cells,
may potentially provide useful quantitative estimates of the miR-
21 expression. Thus, more studies, including examination of the
primary and recurrent tumors in both the adjuvant and neoad-
juvant settings, are needed to better address how the miR-21CC
(and miR-21St) parameters potentially can be used as predictive
biomarkers.
In our previous study of miR-21 in grade 1–2 breast cancers
(12), none of the 24 included cases showed noteworthy expres-
sion in the cancer cells. In the current study, 9 of the 36 cases
(25%) showed intense miR-21CC (miR-21CC score 2 or above).
These miR-21CC cases included both hormone receptor-positive
and -negative cases. Furthermore, miR-21CC did not correlate with
any of the other clinical parameters analyzed in the HER2-positive
tumors. In HER2-negative tumors, we found a significant posi-
tive correlation between miR-21CC and PR. The significance of
this association will need to be further explored. Because miR-21
was found strongly expressed in myoepithelial cells surrounding
occasional CIS structures in some of the lesions, it is tempting
to speculate whether the miR-21CC cases were all of the basal
subtype. However, this is unlikely since some of the miR-21CC
cases were ER-positive. Thus, our data suggest that the miR-21CC
lesions represent an independent group of grade 3 breast can-
cers. The apparent variation in the cellular expression pattern of
miR-21 is an important feature that may impact on targeted ther-
apy since miR-21 in different cell populations may have different
(mRNA) targets. Sempere et al. (40) analyzed breast cancers of
various grades and hormone receptor status and reported fre-
quent expression in cancer cells as well as expression in the breast
cancer-associated fibroblast in some cases. More studies are needed
to better establish whether high miR-21 expression in cancer cells
is confined to grade 3 breast cancers.
As mentioned above, increased miR-21 expression levels are
associated with adverse prognosis in several types of cancer. Exper-
imental studies of tumor models in mice support these find-
ings. In a K-ras-dependent lung cancer model, overexpression
of miR-21 caused increased tumor formation, whereas miR-21
deficiency reduced the tumor formation (41). In a skin carcino-
genesis model, miR-21 deficiency resulted in reduced papilloma
formation (42). In addition, mice lacking the tumor suppressor
p53 showed reduced tumor incidence if also lacking miR-21 (43).
Thus, based on both clinical and experimental findings, miR-21 is
likely a positive driver in the oncogenic process.
Two of the best described miR-21 targets are the tumor suppres-
sors PDCD4 and PTEN. In the context of this study, it is notable
that Huang et al. (44) found that activation of HER2 up-regulates
miR-21 in breast cancer cell lines and causes successive down-
regulation of PDCD4 preventing the tumor cells to enter apop-
tosis. However, PDCD4 is likely a multifunctional protein, whose
role in cancer is only partly understood. PDCD4 was originally
found as a nuclear antigen of proliferating cells (45), while oth-
ers found PDCD4 associated with apoptosis (46, 47). In addition,
PDCD4 was reported to be an inhibitor of neoplastic transforma-
tion and metastasis (48, 49). In breast cancer tissue, PDCD4 is seen
in both normal and malignant epithelial cells and localizes to the
nuclei and/or the cytoplasm (50). It remains to be established if
miR-21 is involved in the regulation of all of these pivotal functions
of PDCD4. Like PDCD4, PTEN has been found in relation to cell
proliferation and apoptosis (51), and its presence has been linked
to drug resistance (30). Lack of PTEN in breast tumor stroma has,
in model systems, been found to strongly enhance transformation
of the mammary epithelium (52, 53). In our study, high levels of
miR-21 in the breast cancer stroma, which would cause miR-21-
directed loss of stromal PTEN, were weakly (p= 0.13) associated
with resistance to adjuvant trastuzumab. Trastuzumab resistance
was reported in patients with breast cancers that were PTEN-
negative in immunohistochemistry (30), however, a systematic
delineation of the presence of PTEN in different cellular compart-
ments in breast cancer lesions is highly warranted, particularly in
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the light of recent studies implying that drug resistance can be
generated through tumor stroma (31–34).
In our previous study of grade 1 and 2 breast cancers (12), we
found that high stromal miR-21 levels determined by image analy-
sis correlated significantly with increased Ki67 proliferation index.
Quantitative assessment by image analysis of the miR-21 ISH sig-
nal in the current grade 3 samples was not accomplished due to
the complex expression patterns as discussed above. However, our
analysis of the miR-21 expression scores in the stroma or cancer
cells in the current grade 3 cancers did not reveal correlation with
the Ki67 index.
In conclusion, we have shown that the miR-21 expression pat-
terns in HER2-positive breast cancers are highly variable being
present in cancer and/or stromal cells, and not linked to known
clinical parameters. In the relatively small group of HER2-positive
tumors studied,our miR-21 ISH analyses did not contribute signif-
icantly to the identification of patients with recurrent disease after
adjuvant trastuzumab. We noted that both miR-21CC and miR-
21St were independent of ER, PR, Ki67, and p53, suggesting that
more extensive studies on trastuzumab resistance are warranted
across additional subgroups of breast cancer. Molecular markers
of trastuzumab resistance like the serum-derived inflammatory
biomarkers (34), or expression of PTEN (30), or truncated HER2
(54) have so far not successfully showed to be clinically valuable
predictive biomarkers.
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